Febs Letters

SEP 22, 2026 · JOURNAL ARTICLE

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

Febs Letters

Acquired resistance to vemurafenib, a BRAF V600E ‐targeted therapy, remains a major challenge in melanoma. The translation initiation factor eIF6 has been implicated in cancer; how

AUG 15, 2026 · JOURNAL ARTICLE

Epigenetic reprogramming of lineage switching in cancer

Febs Letters

This is a narrative review synthesizing mechanistic concepts about epigenetic drivers of cancer cell plasticity, raising questions about therapeutic targets rather than reporting primary empirical data or clinical outcomes.